Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases
AssigneeTargeGen, Inc.
InventorsGlenn Noronha, John D. Hood, Richard M. Soll
Life of this patent
Estimating the term…
Abstract
The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.
Claims21
A method of treating a myeloproliferative disorder, comprising administering to a subject in need thereof an effective amount of a compound having the structure (A):
- wherein:
- X is selected from a group consisting of a bond, O, C═O, SO2, and CH2;
- Y is selected from a group consisting of a bond or NR9;
- or X and Y taken together is a bond;
- each of R1 and R2 is independently selected from a group consisting of H, C1-C6 alkyl, cycloalkyl, or R1 and R2 taken together is a bond;
- or R1 and R2 taken together form a moiety selected from a group consisting of (CH2)m, (CH2)r—S—(CH2)m, (CH2)r—SO—(CH2)m, (CH2)r—SO2—(CH2)m, (CH2)r—NR9—(CH2)m, and (CH2)r—O—(CH2)m;
- each of p, q, r, n, m is independently an integer having the value between 0 and 6,
- R9 is selected from a group consisting of H, C1-C6 alkyl, C1-C6 cycloalkyl, C1-C6 branched alkyl, C1-C6 aminoalkyl, and C1-C6 hydroxyalkyl;
- G0 is selected from a group consisting of N, O, and CH,
- G is CR6, N, or C when bonded to X;
- R5 is methyl;
- wherein each of R6, R7 and R8 is independently selected from a group consisting of H, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 hydroxyalkyl or aminoalkyl, C1-C6 cycloalkyl, C1-C6 alkoxy, a halogen, CF3, OCF3, SO2H, SO2(C1-C6 alkyl), SO2-heterocycle, SO2-cycloalkyl, SO2NH2, SO2N(C1-C6 alkyl)H, SO2N(C1-C6 alkyl)(C1-C6 alkyl), SO2NH(C1-C6 cycloalkyl), SO2NH-heterocycle, (SO2N(C1-C6 branched alkyl)H, NO2, CN, OH, CONH2, CO—(C1-C6 alkyl), COOH, COO—(C1-C6 alkyl), and NHCO—(C1-C6 alkyl), or R6 and R7 taken together, or R7 and R8, taken together, form a moiety independently selected from —CH═CH—CH═CH—, —N═CH—CH═CH—, —CH═N—CH═CH—, or —O—(CH2)n—O—;
- A is selected from a group consisting of NH, and N—(C1-C6 alkyl);
- G1 is CH;
- G2 is selected from the group consisting of CR7, N or NH, with each group R7 being independent of every other group R7;
- and R3 and R4, taken together form a heterocyclic ring system,
- wherein alkyl, alkenyl, alkynyl, cycloalkyl, or heterocycle, for each occurrence if any, are optionally substituted by one or more substituents selected from the group consisting of hydroxy, alkoxy, mercapto, halogen, cyano, nitro, amino, amido, aldehyde, acyl, oxyacyl, carboxyl, sulfonyl, sulfonamide, or sulfuryl;
- or a pharmaceutically acceptable salt thereof.
A method of treating a myeloproliferative disorder, comprising administering to a subject in need thereof a compound selected from the group consisting of compounds having formulas I-CLXII or pharmaceutically acceptable salts thereof:
A method of treating a myeloproliferative disorder, comprising administering to a subject in need thereof an effective amount of the compound:
- or a pharmaceutically acceptable salt thereof.
A method of treating chronic myelogenous leukemia (CML), comprising administering an effective amount of the compound to a subject in need thereof:
- or a pharmaceutically acceptable salt thereof.
A method of treating psoriasis in a patient in need thereof, comprising administering to a subject in need thereof an effective amount of a compound represented by formula (A):
- wherein:
- X is selected from a group consisting of a bond, O, C═O, SO2, and CH2;
- Y is selected from a group consisting of a bond or NR9;
- or X and Y taken together is a bond;
- each of R1 and R2 is independently selected from a group consisting of H, C1-C6 alkyl, cycloalkyl, or R1 and R2 taken together is a bond;
- or R1 and R2 taken together form a moiety selected from a group consisting of (CH2)m, (CH2)r—S—(CH2)m, (CH2)r—SO—(CH2)m, (CH2)r SO2—(CH2)m, (CH2)r—NR9—(CH2)m, and (CH2)r—O—(CH2)m;
- each of p, q, r, n, m is independently an integer having the value between 0 and 6,
- R9 is selected from a group consisting of H, C1-C6 alkyl, C1-C6 cycloalkyl, C1-C6 branched alkyl, C1-C6 aminoalkyl, and C1-C6 hydroxyalkyl;
- G0 is selected from a group consisting of N, O, and CH,
- G is CR6, N, or C when bonded to X;
- R5 is methyl;
- wherein each of R6, R7 and R8 is independently selected from a group consisting of H, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 hydroxyalkyl or aminoalkyl, C1-C6 cycloalkyl, C1-C6 alkoxy, a halogen, CF3, OCF3, SO2H, SO2(C1-C6 alkyl), SO2-heterocycle, SO2-cycloalkyl, SO2NH2, SO2N(C1-C6 alkyl)H, SO2N(C1-C6 alkyl)(C1-C6 alkyl), SO2NH(C1-C6 cycloalkyl), SO2NH-heterocycle, (SO2N(C1-C6 branched alkyl)H, NO2, CN, OH, CONH2, CO—(C1-C6 alkyl), COOH COO—(C1-C6 alkyl), and NHCO—(C1-C6 alkyl), or R6 and R7 taken together, or R7 and R8, taken together, form a moiety independently selected from —CH═CH—CH═CH—, —N═CH—CH═CH—, —CH═N—CH═CH—, or —O—(CH2)n—O—;
- A is selected from a group consisting of NH, and N—(C1-C6 alkyl);
- G1 is CH;
- G2 is selected from the group consisting of CR7, N or NH, with each group R7 being independent of every other group R7;
- and R3 and R4, taken together form a heterocyclic ring system,
- wherein alkyl, alkenyl, alkynyl, cycloalkyl, or heterocycle, for each occurrence if any, are optionally substituted by one or more substituents selected from the group consisting of hydroxy, alkoxy, mercapto, halogen, cyano, nitro, amino, amido, aldehyde, acyl, oxyacyl, carboxyl, sulfonyl, sulfonamide, or sulfuryl;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.